This article is more than 5 years old. Information may no longer be current.
VIDEO: Risk-adapted approach should guide use of extended adjuvant therapy
Click Here to Manage Email Alerts
SAN ANTONIO — Alberto J. Montero, MD, of Cleveland Clinic discusses results of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium.
Researchers in the randomized, double blind, placebo-controlled trial assessed whether 5 years of letrozole extended DFS compared with placebo among postmenopausal women with hormone receptor–positive breast cancer who already completed 5 years of hormonal therapy with an aromatase inhibitor or tamoxifen followed by an aromatase inhibitor.
Extended adjuvant endocrine therapy with letrozole conferred no significant survival benefit. Extended therapy also increased risk for arterial thrombotic events.
“The increased toxicity is concerning, particularly in older patients,” Montero told HemOnc Today.
However, extended therapy could be beneficial for certain patients, he said.
“The bottom line is that you should take a risk-adapted personalized approach,” Montero said. “This is not something that should be applied to everyone uniformly.” – by Kristie L. Kahl
Reference:
Mamounas P, et al. Abstract S1-05. Presented at: San Antonio Breast Cancer Symposium; Dec. 6-10, 2016; San Antonio, Texas.
Disclosure: Montero reports no relevant financial disclosures.